Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Cell Activation
100%
Human Immunodeficiency Virus
100%
Immunocompetent Cell
100%
Impaired Glucose Tolerance
100%
Inflammation
100%
Sitagliptin
100%
Placebo
55%
Adipose Tissue
44%
Antiretroviral Therapy
33%
C Reactive Protein
22%
Glucose Tolerance
22%
Hormone Receptor
22%
Mucin
22%
C-X-C Motif Chemokine 10
22%
Oral
22%
Glucose
22%
Leukocyte
11%
Myocardial Infarction
11%
Apoplexy
11%
Insulin Sensitivity
11%
Cell Surface Receptor
11%
Enzyme Linked Immunosorbent Assay
11%
Vascular Disease
11%
Histiocyte
11%
Human Immunodeficiency Virus Infection
11%
Monocyte Chemotactic Protein 1
11%
Antiinflammatory Activity
11%
Hyperinsulinemia
11%
Dipeptidyl Peptidase-4 Inhibitor
11%
Monocyte Chemotactic Protein
11%
Dipeptidyl Peptidase IV
11%
Cardiovascular System
11%
Messenger RNA
11%
Diseases
11%
Area under the Curve
11%
Keyphrases
Inflammation
100%
HIV+
100%
Immune Activation
100%
Impaired Glucose Tolerance
100%
Sitagliptin
100%
Placebo
44%
Combined Antiretroviral Therapy (cART)
33%
CXCL10
22%
High-sensitivity C-reactive Protein (hs-CRP)
22%
Monocyte Chemoattractant protein-1 (MCP-1)
22%
Receptor 1
22%
EGF-like
22%
Hormone Receptor
22%
Mucin
22%
Dipeptidyl peptidase-4 (DPP-4)
22%
Glucose Tolerance
11%
Glucose-insulin System
11%
MRNA Expression
11%
Leukocytes
11%
Cell Surface Receptor
11%
High Incidence
11%
Randomized Placebo-controlled Trial
11%
Myocardial Infarction
11%
Prospective Randomized Trial
11%
Immunomodulatory Effect
11%
Inflammatory Cells
11%
Academic Medical Centers
11%
Adipose Tissue
11%
Vascular Disease
11%
Oral Glucose Tolerance Test
11%
Double-blind Trial
11%
Incidence Rate
11%
Hyperinsulinemia
11%
HIV Infection
11%
HIV Disease
11%
Anti-inflammatory Effect
11%
Low-grade Inflammation
11%
Activation Markers
11%
Inflammation Cells
11%
Oral Glucose
11%
CD26
11%
Systemic Immune Response
11%
Effective Combination
11%
Glucose Area under the Curve
11%
HIV-infected Patients
11%
Insulin Sensitivity Index
11%